MedPath

Ankasa Regenerative Therapeutics, Inc.

Ankasa Regenerative Therapeutics, Inc. logo
🇺🇸United States
Ownership
Holding
Established
2014-01-01
Employees
1K
Market Cap
-
Website
http://ankasaregenerativetherapeutics.com

Clinical Trials

1

Active:0
Completed:0

Trial Phases

1 Phases

Phase 1:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials

Phase 1
1 (100.0%)

Safety Evaluation of ART352-L in Subjects Undergoing Posterolateral Spinal Fusion

Phase 1
Conditions
Degenerative Spondylolisthesis
First Posted Date
2020-05-07
Last Posted Date
2020-10-12
Lead Sponsor
Ankasa Regenerative Therapeutics, Inc.
Target Recruit Count
12
Registration Number
NCT04378543
Locations
🇺🇸

Keck School of Medicine, University of Southern California, Los Angeles, California, United States

🇺🇸

Mayo Clinic, Rochester, Minnesota, United States

🇺🇸

Wexner Medical Center, The Ohio State University, Columbus, Ohio, United States

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.